Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Joshua Cohen Sells 136,193 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Joshua Cohen sold 136,193 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $13.59, for a total value of $1,850,862.87. Following the completion of the transaction, the chief executive officer directly owned 3,378,546 shares in the company, valued at approximately $45,914,440.14. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Amylyx Pharmaceuticals Stock Performance

AMLX opened at $16.55 on Wednesday. The stock has a fifty day moving average of $13.17 and a 200-day moving average of $11.75. The company has a market capitalization of $1.82 billion, a P/E ratio of -9.19 and a beta of -0.31. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $16.96.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. On average, equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System bought a new position in Amylyx Pharmaceuticals in the second quarter valued at about $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $45,000. BNP Paribas Financial Markets increased its stake in shares of Amylyx Pharmaceuticals by 433.2% in the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after buying an additional 5,904 shares during the period. Legal & General Group Plc bought a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $47,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Amylyx Pharmaceuticals during the 3rd quarter worth approximately $48,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AMLX. Lifesci Capital raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 27th. HC Wainwright raised their target price on Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the company a “buy” rating in a report on Friday, November 7th. Robert W. Baird lifted their price target on Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Citigroup upped their price objective on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.